FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria

Share this content:
FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria
FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria

MONDAY, March 6, 2017 (HealthDay News) -- Noctiva (desmopressin acetate) nasal spray has been approved by the U.S. Food and Drug Administration to treat frequent urination at night due to nocturnal polyuria.

Noctiva is the first drug approved to treat nocturnal polyuria in the United States, the FDA added. Noctiva, taken about 30 minutes before bed, is designed to increase absorption of water through the kidneys, decreasing urine production. Before prescribing Noctiva, health care providers should confirm overproduction of urine at night by collecting a 24-hour urine sample, the FDA recommended. They should also make sure a patient's habits, such as excessive consumption of fluids, may not be contributing to the problem.

The drug's effectiveness was evaluated in two, 12-week clinical trials involving 1,045 patients aged 50 and older with nocturnal polyuria. The drug's label warns of an elevated risk for hyponatremia, which if severe could be life threatening if not promptly treated, the FDA said.

Noctiva should not be used by patients with symptomatic congestive heart failure or uncontrolled hypertension, the FDA added. It should also not be used by pregnant women or children. The drug's most common side effects include nasal discomfort, nasal congestion, sneezing, an increase in blood pressure, back pain, nose bleed, bronchitis, and dizziness.

Noctiva is marketed by Milford, Pa.- based Renaissance Lakewood for Serenity Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Risk of Adverse Outcomes for Births to Young CA Survivors

Higher Risk of Adverse Outcomes for Births to ...

Increased risks among live births for adolescent and young adult cancer survivors

Many Youths With Diabetes Not Receiving Eye Examinations

Many Youths With Diabetes Not Receiving Eye Examinations

Racial minorities less likely to undergo eye exam; increasing net worth increases likelihood of eye exam

Mortality Risk Impacts Colon CA Screening in Dialysis Patients

Mortality Risk Impacts Colon CA Screening in Dialysis ...

Higher rate of screening among patients most likely to receive a transplant

is free, fast, and customized just for you!

Already a member?

Sign In Now »